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Essentials
• Acquired thrombotic thrombocytopenic purpura
(aTTP) is linked with significant morbidity/mortality.
• Caplacizumab’s effect on major thromboembolic (TE)
events, exacerbations and death was studied.
• Fewer caplacizumab-treated patients had a major TE
event, an exacerbation, or died versus placebo.
• Caplacizumab has the potential to reduce the acute
morbidity and mortality associated with aTTP.
Summary. Background: Acquired thrombotic thrombocy-
topenic purpura (aTTP) is a life-threatening autoimmune
thrombotic microangiopathy. In spite of treatment with
plasma exchange and immunosuppression, patients remain
at risk for thrombotic complications, exacerbations, and
death. In the phase II TITAN study, treatment with capla-
cizumab, an anti-von Willebrand factor Nanobody was
shown to reduce the time to confirmed platelet count nor-
malization and exacerbations during treatment. Objective:
The clinical benefit of caplacizumabwas further investigated
in a post hoc analysis of the incidence of major thromboem-
bolic events and exacerbations during the study drug
treatment period and thrombotic thrombocytopenic
purpura-related death during the study. Methods: The
Standardized Medical Dictionary for Regulatory Activities
(MedDRA) Query (SMQ) for ‘embolic and thrombotic
events’ was run to investigate the occurrence of major
thromboembolic events and exacerbations in the safety pop-
ulation of the TITAN study, which consisted of 72 patients,
of whom 35 received caplacizumab and 37 received place-
bo. Results: Four events (one pulmonary embolism and
three aTTP exacerbations) were reported in four patients in
the caplacizumab group, and 20 such events were reported
in 14 patients in the placebo group (two acute myocardial
infarctions, one ischemic stroke, one hemorrhagic stroke,
one pulmonary embolism, one deep vein thrombosis, one
venous thrombosis, and 13 aTTP exacerbations). Two of
the placebo-treated patients died from aTTP during the
study. Conclusion: In total, 11.4% of caplacizumab-treated
patients and 43.2% of placebo-treated patients experienced
one or more major thromboembolic events, experienced an
exacerbation, or died. This analysis shows the potential for
caplacizumab to reduce the risk of major thromboembolic
morbidities andmortality associated with aTTP.
Keywords: caplacizumab; morbidity; mortality; purpura,
thrombotic thrombocytopenic; von Willebrand factor.
Introduction
Acquired thrombotic thrombocytopenic purpura (aTTP)
is a rare, life-threatening autoimmune blood clotting dis-
order, manifested by systemic microvascular thrombosis
leading to profound thrombocytopenia, hemolytic ane-
mia, and organ ischemia [1]. It is caused by inhibitory
autoantibodies against the von Willebrand factor
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(VWF)-cleaving protease ADAMTS-13 [2]. Decreased
ADAMTS-13 activity leads to an accumulation of ultra
large (UL) VWF multimers, which bind to platelets and
induce the formation of microthrombi, causing tissue
ischemia and organ dysfunction, and possibly resulting in
overt major thromboembolic complications, such as
stroke, myocardial infarction, and arterial and venous
thrombosis [3,4]. Episodes of aTTP are associated with
an acute mortality rate of up to 20% [5], with most
deaths occurring within 30 days of diagnosis [6] (median
of 9 days [3]).
The current mainstay of aTTP treatment is plasma
exchange (PE) in conjunction with immunosuppression
(e.g. with glucocorticoids and/or rituximab) [7]. PE
removes UL VWF and autoantibodies and replenishes
ADAMTS-13, whereas immunosuppression inhibits
autoantibody formation. However, current treatment has
a slow onset of action and does not immediately address
the pathophysiologic platelet aggregation that leads to the
formation of microthrombi [8].
Caplacizumab, an anti-VWF Nanobody, immediately
blocks the interaction of UL VWF with platelets, and
therefore inhibits further formation and accumulation of
microthrombi. The efficacy and safety of caplacizumab
have been evaluated in the phase II TITAN study [9].
Seventy-five patients with a clinical diagnosis of aTTP
were randomized. Although ADAMTS-13 activity was not
included in the eligibility criteria, 77% of patients had a
baseline ADAMTS-13 activity of < 10%, and 11% had
ADAMTS-13 activity levels of ≥ 10%; baseline
ADAMTS-13 results were missing for the remaining 12%.
The results of the study showed that treatment with capla-
cizumab resulted in 39% faster normalization of platelet
counts than treatment with placebo [9]. This translated
into a reduced need for PE treatment (7.7 days versus
11.7 days for placebo). Treatment with caplacizumab was
also associated with a higher complete remission rate (i.e.
confirmed platelet count response and absence of exacer-
bation) (81% versus 46% for placebo), fewer exacerba-
tions during the treatment period (three patients versus 11
for placebo), and a reduction in the percentage of patients
refractory to treatment (5.7% versus 21.6%, or 0% versus
10.8% for placebo, depending on the definition used for
refractoriness [10]). Seven patients in the caplacizumab
group experienced a relapse within 10 days after stopping
use of the study drug. All had ADAMTS-13 levels that
remained below 10%, suggesting unresolved autoimmune
activity. The main safety finding was increased mild bleed-
ing, mainly mucocutaneous, without a requirement for
VWF/factor VIII administration.
Here, we report the results of a post hoc analysis of
the TITAN study data that evaluated the impact of
treatment with caplacizumab on the incidence of major
thromboembolic events and exacerbations during the
study drug treatment and aTTP-related mortality during
the study.
Methods
The phase II TITAN study was a randomized, single-
blind, placebo-controlled, multicenter study in adults
experiencing an acute episode of aTTP [9]. The main
inclusion criteria were a clinical diagnosis of aTTP requir-
ing the initiation of PE, and a platelet count of
< 100 000 mm–3.
Seventy-five patients were randomized in a 1 : 1 ratio
to receive either 10 mg of caplacizumab or placebo daily
in addition to standard of care throughout the PE period
and for 30 days thereafter. The safety population (i.e. all
patients who received at least one dose of study drug)
consisted of 72 patients, of whom 35 received capla-
cizumab and 37 received placebo, and was used for this
analysis.
Major thromboembolic events were retrieved from the
study’s safety database (i.e. all adverse events as reported
by the Investigators) by use of the Standardized Medical
Dictionary for Regulatory Activities (MedDRA) Query
(SMQ) for ‘embolic and thrombotic events’. This query
contains predetermined sets of MedDRA preferred terms
for ‘arterial’, ‘venous’ and ‘vessel type unspecified and
mixed arterial and venous’ events (MedDRA version 19.1
was used). Medical review of the output resulted in exclu-
sion of two reported treatment-emergent adverse events
from the analysis. One event was reported as ‘thrombotic
catheter’, but was an obstruction within the malfunction-
ing catheter itself and not a venous thrombosis. The sec-
ond event was reported as ‘thrombocytopenia’, but was
present at baseline. Transient ischemic attacks were not
considered to be major thromboembolic events, and were
therefore also not included in this analysis. ‘Thrombotic
thrombocytopenic purpura’ is a predefined term in the
SMQ ‘thrombotic and embolic events’. aTTP exacerba-
tions are captured in the SMQ output, as they reflect
acute worsening of the presenting episode. They are
reported as ‘aTTP exacerbations’. Thrombotic thrombo-
cytopenic purpura (TTP)-related mortality during the
study was evaluated on the basis of adverse event report-
ing, with relatedness to aTTP as judged and reported by
the investigator. The number of events and the number
and percentage of patients having an event or who died
were summarized by treatment group for the safety popu-
lation. The event times of major thromboembolic events,
TTP exacerbations and TTP-related death were presented
graphically by treatment group.
Results and discussion
After medical review of the events defined by the SMQ, a
total of eight major thromboembolic events were identi-
fied (Table 1). One major thromboembolic event was
reported in one patient in the caplacizumab group: pul-
monary embolism. In the placebo group, seven major
thromboembolic events were reported in six patients: two
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acute myocardial infarctions in two patients (reported
verbatim terms were ‘non S-T elevation myocardial
infarction’ and ‘acute myocardial infarction’, respec-
tively), one ischemic stroke and one hemorrhagic stroke
in one patient (reported as separate events within the
same patient; both events had the same onset and end
date), one pulmonary embolism, one deep vein thrombo-
sis (the reported verbatim term was ‘right lower extremi-
ties deep vein thrombosis’), and one venous thrombosis
(the reported verbatim term was ‘gemellar muscular veins
thrombosis’). The frequency of major thromboembolic
events in the placebo group was consistent with that
reported in the literature [3,4].
The output of the SMQ also reflects the aTTP exacer-
bations that were reported as serious adverse events dur-
ing the study drug treatment period. In total, three aTTP
exacerbations occurred in three caplacizumab-treated
patients, and 13 aTTP exacerbations occurred in 11 pla-
cebo-treated patients (Table 1). TTP exacerbations
re-expose patients to the same acute thrombotic risks of
the disease. In the French TTP Registry, death was
reported in 14% of the patients with an exacerbation [11].
Two patients died during the study, both in the placebo
group (Table 1). One patient died from severe refractory
TTP, after 22 days of intensified daily PE treatment and
immunosuppressive treatment (i.e. cyclophosphamide and
rituximab). The second patient died from a cerebral hem-
orrhage after 10 days of daily PE, throughout which pla-
telet counts were in the range of 30 9 109 L–1. These
findings are consistent with published data showing that
refractoriness to treatment is an indicator of a poor
prognosis for survival in patients with aTTP [12–14]. It is
of note that caplacizumab has been shown to reduce the
incidence of refractoriness to therapy [10].
The composite analysis of major thromboembolic
events and aTTP exacerbations during the study drug
treatment period and aTTP-related deaths during the
study showed that 11.4% of caplacizumab-treated
patients and 43.2% of placebo-treated patients experi-
enced one or more thromboembolic events, experienced
an exacerbation, or died, which represents a 74% reduc-
tion (Table 1). All reported events occurred in patients
with a baseline ADAMTS-13 activity of < 10%, except
for three events in three placebo-treated patients: one
patient with a myocardial infarction (missing baseline
ADAMTS-13 result), one patient with a fatal cerebral
hemorrhage (baseline ADAMTS-13 activity of 75%), and
one patient with an exacerbation (baseline ADAMTS-13
activity of 90%). It is of note that, if these patients had
been excluded from the analysis, the results would have
still favored caplacizumab.
The time-to-event analysis indicates that the majority
of these events occurred within the first 30 days of enroll-
ment (Fig. 1). Most of the major thromboembolic events
occurred during the daily PE period, whereas, by defini-
tion, aTTP exacerbations occurred after an initial platelet
response had been reached (range: within 7–30 days of
enrollment). These data confirm that patients experiencing
an aTTP episode are at the greatest risk of life-threatening
complications during this acute period.
Major thromboembolic events may contribute to long-
term cognitive and physical deficits of patients
Table 1 Treatment-emergent major thromboembolic events and acquired thrombotic thrombocytopenic purpura (aTTP) exacerbations during
the treatment period and overall aTTP-related mortality in the safety population of the phase II TITAN study
Caplacizumab (N = 35) Placebo (N = 37)
No. of events No. of patients % of patients No. of events No. of patients % of patients
Major thromboembolic events (based on the SMQ, by preferred term)
Acute myocardial infarction* 0 0 0 2 2 5.4
Pulmonary embolism 1 1 2.9 1 1 2.7
Deep vein thrombosis† 0 0 0 1 1 2.7
Venous thrombosis‡ 0 0 0 1 1 2.7
Ischemic stroke§ 0 0 0 1 1 2.7
Hemorrhagic stroke§ 0 0 0 1 1 2.7
aTTP exacerbations (based on the SMQ, by preferred term)
Thrombotic thrombocytopenic purpura¶ 3 3 8.6 13 11 29.7
aTTP-related mortality
Deaths related to TTP 0 0 0 2 2 5.4
Total 4 4** 11.4 22 16** 43.2
SMQ, Standardized MedDRA (Medical Dictionary for Regulatory Activities) Query; TTP, thrombotic thrombocytopenic purpura. *Verbatim
terms: one acute myocardial infarction was reported as ‘non S-T elevation myocardial infarction’, and one as ‘acute myocardial infarction’.
†Verbatim term: ‘right lower extremities deep vein thrombosis’. ‡Verbatim term: ‘gemellar muscular veins thrombosis’. §The ischemic stroke
and hemorrhagic stroke were reported as separate events within the same patient. Both events had the same onset and end date. ¶This pre-
ferred term consisted of recurrences of aTTP during the treatment period, defined and reported per protocol as exacerbations of TTP. **A
patient may have experienced more than one event.
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experiencing an episode of aTTP [15–20]. The impact of
treatment with caplacizumab on the frequency of major
thromboembolic events and exacerbations in the phase II
TITAN study was highly clinically meaningful. By reduc-
ing acute thromboembolic complications and exacerba-
tions, treatment with caplacizumab may also improve
longer-term outcomes. A phase III study of caplacizumab
in patients with aTTP is ongoing (NCT02553317), and
will prospectively evaluate these important clinical end-
points as a composite endpoint consisting of major
thromboembolic events, exacerbations, and aTTP-related
death. In addition, patients who completed the phase III
study will be followed in a long-term follow-up study
(NCT02878603).
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